Novel approaches to propagate molluscum contagiosum virus in cell culture
Novel approaches to propagate molluscum contagiosum virus in cell culture
批准号:
9089855
负责人:
Stuart N. Isaacs
金额:
$24.62万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2019-06-30
关键词:
3-DimensionalAdultAntiviral ResponseAttenuatedBenignBiologyCell CommunicationCell Culture SystemCell Culture TechniquesCell LineCell modelCellsChildCollectionCommunitiesComplementCultured CellsDevelopmentDistressElementsEnvironmentEpidermisExtramural ActivitiesFamilyFundingFutureGenesGoalsGrowthHIVHealthHealth Care CostsHumanImmuneImmunocompromised HostIn VitroIndividualInfectionInfectious Skin DiseasesKnowledgeLesionLife Cycle StagesLinkMedicalModelingMolluscum ContagiosumMolluscum contagiosum virusOffice VisitsOrthopoxvirusParentsPathway interactionsPatientsPhysiologyPopulationPoxviridaePropertyProteinsResearchResearch ProposalsRoleScientistSignal PathwaySignal TransductionSkinSkin TissueStagingSystemTechnical ExpertiseTestingTherapeuticTissuesUnited States National Institutes of HealthViralViral GenomeVirusVirus DiseasesVirus ReplicationWorkbaseburden of illnesscellular targetingcostemotional distressgene productimmortalized cellimmunosuppressedin vivoinsightkeratinocytenovel strategiespathogenskin barrierskin disorderskin disorder diagnosisskin lesiontherapeutic developmenttransmission processtwo-dimensional
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Molluscum contagiosum (MC) is a common skin infection caused by molluscum contagiosum virus (MoCV), a dermatotropic poxvirus. MC presents as single to multiple skin lesions that last from months to years. Transmission is by direct skin-to-skin contact or by indirect contact with fomites. MC lesions are solely restricted t human skin and occur in children, adults, and immunosuppressed individuals. While the lesions are benign, they are often unsightly and thus are psychologically distressful to patients and parents. MC occurs in 2-10% of the worldwide population. In the USA, it constitutes about 1% of all diagnosed skin disorders and occurs in almost 5% of children. In immune-compromised individuals, MC is severe and protracted. Between 5- 18% of HIV patients have MC. Despite the huge burden of disease and the associated significant healthcare costs, there are no extramural NIH-funded projects that specifically study this virus. The major impediment in researching MoCV and finding potential therapeutic cures for MC has been the inability of MoCV to propagate in any type of cultured cells. The objective of this R21 project is to use various novel strategies to identify a system that would allow replication of MoCV in cell culture. We hypothesize that the inability to propagate MoCV in cells in culture is linked to the inability of MoCV to downregulate a cell's innate anti-viral responses. It also reflects unique properties of the human epidermis in vivo that are not reproduced during culture in vitro. We hypothesize that this block in productive infection can be overcome by manipulation of cells in culture to create an intracellular environment that would allow the full MoCV life cycle to be carried out. By establishing models for the growth of MoCV in cell culture and identifying the factors that regulate its replication in keratinocytes, we will gain insights into unique features of skin cells
that allow dermatotropic viruses like MoCV to grow and spread in the skin, which will, in the future, serve as a basis for further study and potential development of therapeutics. To test these concepts we will: * Determine at what stage MoCV infection is blocked in both primary human keratinocytes and immortalized cells * Manipulate the host cell microenvironment with poxviral proteins not expressed by MoCV * Manipulate the host cell innate-antiviral responses by targeting cellular proteins By combining Penn's on-campus research expertise in poxvirology and human epidermal biology, we believe that we are poised to make a major advance in poxvirology and discover a way to allow the propagation and spread of MoCV in cell culture systems. Support through this R21 application will allow us begin the steps to reach this important and significant goal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
XXIII International Poxvirus, Asfarvirus, and Iridovirus Conference
-
批准号:9993673
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2021
-
负责人:Stuart N. Isaacs
-
依托单位:
Enhancement and Expansion: Penn Neurophysiology and Behavior Testing Facility
-
批准号:9120117
-
项目类别:
-
资助金额:$49.55万
-
财政年份:2016
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:7901695
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2009
-
负责人:Stuart N. Isaacs
-
依托单位:
Optimizing the formulation of a protein based smallpox vaccine
-
批准号:7802243
-
项目类别:
-
资助金额:$35.73万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Optimizing the formulation of a protein based smallpox vaccine
-
批准号:7616506
-
项目类别:
-
资助金额:$56.78万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Optimizing the formulation of a protein based smallpox vaccine
-
批准号:8056790
-
项目类别:
-
资助金额:$49.07万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Optimizing the formulation of a protein based smallpox vaccine
-
批准号:8259455
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Optimizing the formulation of a protein based smallpox vaccine
-
批准号:7454535
-
项目类别:
-
资助金额:$53.89万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Poxvirus
-
批准号:7678786
-
项目类别:
-
资助金额:$69.17万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
New Opportunities - Mechanisms of Early Vaccinia Viral Morphogensis
-
批准号:7680587
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2008
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:7247181
-
项目类别:
-
资助金额:$31.17万
-
财政年份:2005
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:7448668
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2005
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:7091421
-
项目类别:
-
资助金额:$31.08万
-
财政年份:2005
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:7628097
-
项目类别:
-
资助金额:$32.44万
-
财政年份:2005
-
负责人:Stuart N. Isaacs
-
依托单位:
Smallpox vaccine and vaccinia complement control protein
-
批准号:6988333
-
项目类别:
-
资助金额:$33.33万
-
财政年份:2005
-
负责人:Stuart N. Isaacs
-
依托单位:
VACCINIA B5R PROTEIN IN SPREAD IMMUNE EVASION, VACCINES
-
批准号:6632256
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2001
-
负责人:Stuart N. Isaacs
-
依托单位:
VACCINIA B5R PROTEIN IN SPREAD IMMUNE EVASION, VACCINES
-
批准号:6890918
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2001
-
负责人:Stuart N. Isaacs
-
依托单位:
VACCINIA B5R PROTEIN IN SPREAD IMMUNE EVASION, VACCINES
-
批准号:6511250
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2001
-
负责人:Stuart N. Isaacs
-
依托单位:
VACCINIA B5R PROTEIN IN SPREAD IMMUNE EVASION, VACCINES
-
批准号:6732771
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2001
-
负责人:Stuart N. Isaacs
-
依托单位:
VACCINIA B5R PROTEIN IN SPREAD IMMUNE EVASION, VACCINES
-
批准号:6346871
-
项目类别:
-
资助金额:$33.88万
-
财政年份:2001
-
负责人:Stuart N. Isaacs
-
依托单位:
海外基金